- Home
- ALVR vs MRNS Comparison
ALVR vs MRNS Comparison
Compare ALVR & MRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALVR
- MRNS
- Stock Information
- Founded
- ALVR 2013
- MRNS 2003
- Country
- ALVR United States
- MRNS United States
- Employees
- ALVR N/A
- MRNS N/A
- Industry
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- MRNS Biotechnology: Pharmaceutical Preparations
- Sector
- ALVR Health Care
- MRNS Health Care
- Exchange
- ALVR Nasdaq
- MRNS Nasdaq
- Market Cap
- ALVR 87.7M
- MRNS 104.7M
- IPO Year
- ALVR 2020
- MRNS 2014
- Fundamental
- Price
- ALVR $0.94
- MRNS $0.31
- Analyst Decision
- ALVR Sell
- MRNS Buy
- Analyst Count
- ALVR 5
- MRNS 12
- Target Price
- ALVR $1.00
- MRNS $4.56
- AVG Volume (30 Days)
- ALVR 155.6K
- MRNS 5.7M
- Earning Date
- ALVR 11-04-2024
- MRNS 11-05-2024
- Dividend Yield
- ALVR N/A
- MRNS N/A
- EPS Growth
- ALVR N/A
- MRNS N/A
- EPS
- ALVR N/A
- MRNS N/A
- Revenue
- ALVR N/A
- MRNS $30,263,000.00
- Revenue This Year
- ALVR N/A
- MRNS $21.18
- Revenue Next Year
- ALVR N/A
- MRNS $56.42
- P/E Ratio
- ALVR N/A
- MRNS N/A
- Revenue Growth
- ALVR N/A
- MRNS 16.56
- 52 Week Low
- ALVR $0.58
- MRNS $0.26
- 52 Week High
- ALVR $2.49
- MRNS $11.26
- Technical
- Relative Strength Index (RSI)
- ALVR 69.10
- MRNS 21.75
- Support Level
- ALVR $0.74
- MRNS $0.29
- Resistance Level
- ALVR $0.91
- MRNS $1.96
- Average True Range (ATR)
- ALVR 0.06
- MRNS 0.12
- MACD
- ALVR 0.01
- MRNS -0.18
- Stochastic Oscillator
- ALVR 94.50
- MRNS 2.41
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.